Lobaplatin

洛铂

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLobaplatin
Drug Alias NameLobaplatino乐铂洛巴铂LobaplatinumLobaplatine +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsSmall Cell Lung CarcinomaBreast NeoplasmsNasopharyngeal Carcinoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesHainan Changan International Pharmaceutical Co Ltd
Inactive CompaniesGuangxi Medical UniversitySun Yat-Sen University
Active IndicationsSmall Cell Lung CarcinomaBreast NeoplasmsCarcinoma, Ovarian Epithelial +[4] 
Inactive IndicationsNasopharyngeal CarcinomaCarcinoma, Hepatocellular

Other Information

ATC CodeL01XA
Related LinksN/A